Moderna, Inc. $MRNA Shares Newly Purchased by N.F.U. MUTUAL UNIT MANAGERS Ltd

N.F.U. MUTUAL UNIT MANAGERS Ltd acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 8,310 shares of the company’s stock, valued at approximately $1,599,000.

A number of other hedge funds have also made changes to their positions in MRNA. Ethic Inc. raised its holdings in Moderna by 23.6% during the third quarter. Ethic Inc. now owns 19,394 shares of the company’s stock worth $3,735,000 after purchasing an additional 3,700 shares in the last quarter. Merck & Co. Inc. acquired a new position in shares of Moderna in the 2nd quarter valued at $161,642,545. Bank of New York Mellon Corp acquired a new position in shares of Moderna in the 2nd quarter valued at $119,168,000. TD Waterhouse Canada Inc. boosted its holdings in shares of Moderna by 2,042.6% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company’s stock valued at $13,722,000 after buying an additional 69,203 shares in the last quarter. Finally, Contravisory Investment Management Inc. grew its position in shares of Moderna by 1,387.6% in the 2nd quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock valued at $1,696,000 after buying an additional 22,590 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. lifted their price target on shares of Moderna from $77.00 to $102.00 and gave the stock an “underweight” rating in a research note on Tuesday. Barclays boosted their price target on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 24th. Sanford C. Bernstein restated a “market perform” rating on shares of Moderna in a research note on Friday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Moderna in a report on Tuesday, September 22nd. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $120.25.

View Our Latest Analysis on MRNA

Insider Buying and Selling

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 275,626 shares of company stock worth $50,776,076 in the last 90 days. Company insiders own 10.80% of the company’s stock.

Trending Headlines about Moderna

These are some of the MRNA headlines that stood out recently:

  • Positive Sentiment: Moderna’s personalized melanoma vaccine, used with Merck’s Keytruda, reduced the risk of recurrence or death in a Phase 3 trial. The results support the potential of its oncology pipeline, although positive trial news has not prevented the recent pullback. Article: Moderna's Cancer Vaccine Worked
  • Positive Sentiment: A report says Morgan Stanley sees potential for substantial share-price appreciation, offering a more optimistic view amid recent volatility. Article: Morgan Stanley Forecasts Strong Price Appreciation
  • Negative Sentiment: President Stephen Hoge sold shares in transactions reported for November 16 and 17, and coverage noted the stock fell below its 50-day moving average. The sales were made under a pre-arranged Rule 10b5-1 plan, so they do not necessarily signal a change in his view of the company, but they may add to near-term selling pressure. Article: Moderna President Sells Shares

Moderna Price Performance

MRNA stock opened at $194.18 on Friday. The company has a market capitalization of $78.57 billion, a P/E ratio of -27.35 and a beta of 1.16. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $280.80. The business has a 50 day simple moving average of $207.87 and a 200-day simple moving average of $100.37. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The company’s revenue for the quarter was up 29.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.51) earnings per share. As a group, equities analysts anticipate that Moderna, Inc. will post -5.23 EPS for the current year.

About Moderna

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Featured Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.